Role of protein arginine methyltransferase 1 in obesity‐related metabolic disorders: Research progress and implications

Abstract Obesity has become a major global problem that significantly confers an increased risk of developing life‐threatening complications, including type 2 diabetes mellitus, fatty liver disease and cardiovascular diseases. Protein arginine methyltransferases (PRMTs) are enzymes that catalyse the methylation of target proteins. They are ubiquitous in eukaryotes and regulate transcription, splicing, cell metabolism and RNA biology. As a key, epigenetically modified enzyme, protein arginine methyltransferase 1 (PRMT1) is involved in obesity‐related metabolic processes, such as lipid metabolism, the insulin signalling pathway, energy balance and inflammation, and plays an important role in the pathology of obesity‐related metabolic disorders. This review summarizes recent research on the role of PRMT1 in obesity‐related metabolic disorders. The primary objective was to comprehensively elucidate the functional role and regulatory mechanisms of PRMT1. Moreover, this study attempts to review the pathogenesis of PRMT1‐mediated obesity‐related metabolic disorders, thereby offering pivotal information for further studies and clinical treatment.